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Background
The ''Good Participatory Practice Guidelines for biomedi-
cal HIV prevention trials'' were published by UNAIDS and
AVAC in November, 2007. Since publication of the guide-
lines, AVAC, together with 12 partner organizations, gath-
ered data about their utilization, as well as stakeholder
views of their appropriateness and usefulness.
Methods
Between June 2008 and May 2009, AVAC collaborated
with biomedical HIV prevention stakeholders from multi-
ple countries on activities that raised awareness of and
generated feedback on the guidelines. Diverse audiences
targeted by these consultations included: trial site staff
and volunteers, CABs, IRB members, NGO representa-
tives, sex workers, PLWHA, IDUs, and other community
members. Collaborating partners oriented stakeholders to
the GPP guidelines and conducted interviews, focus group
discussions and consultations to gather data on stake-
holders' views of the guidelines, and recommendations
for implementation and revisions, if necessary. Data were
gathered by each partner and AVAC compiled the results.
Results
Data from 21 countries indicated support of the guide-
lines as well as recommendations for their implementa-
tion and improvement. While stakeholders said the
guidelines are comprehensive and should be imple-
mented across trial sites, the language and format of the
guidelines could be improved for better understanding
and utilization by trial sites and community members
alike.
Conclusion
There was widespread agreement that the GPP guidelines
are vital as there was no previous normative agency guid-
ance document to guide trial site sponsors and imple-
menters on community engagement. Stakeholders
included in the consultations recommend that trial sites
be required to follow the GPP guidelines, much like with
Good Clinical Practice. UNAIDS should formally notify
trial sponsors, implementers and governments about the
current version of the guidelines through its country
offices. While the current version of the guidelines is being
rolled out globally, AVAC and UNAIDS should convene a
committee to revise the guidelines to make the document
more useful.
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